SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:gup.ub.gu.se/309489"
 

Search: onr:"swepub:oai:gup.ub.gu.se/309489" > Multifaceted pathog...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Multifaceted pathogenesis of liver steatosis in inflammatory bowel disease: a systematic review

Spagnuolo, R. (author)
Abenavoli, L. (author)
Corea, A. (author)
show more...
Larussa, T. (author)
Mancina, Rosellina Margherita (author)
Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för molekylär och klinisk medicin,Institute of Medicine, Department of Molecular and Clinical Medicine
Cosco, C. (author)
Luzza, F. (author)
Doldo, P. (author)
show less...
 (creator_code:org_t)
2021
2021
English.
In: European Review for Medical and Pharmacological Sciences. - 1128-3602. ; 25:18, s. 5818-5825
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • OBJECTIVE: Non-Alcoholic Fatty Liver Disease (NAFLD), as a hepatic manifestation of metabolic syndrome (MET)-related obesity, insulin resistance, dyslipidemia, and hypertension, is the main cause of chronic liver disease. Inflammatory Bowel Diseases (IBD). (Crohn's Disease (CD) and Ulcerative Colitis (UC)). are often associated with extraintestinal manifestations. Of these. NAFLD is one of the most frequently reported. To highlight the etiopathogenesis of NAFLD in IBD, we performed a systematic review emphasizing the relationship between NAFLD genetic alterations, metabolic syndrome, and drugs. MATERIALS AND METHODS: According to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Statement (PRISMA) criteria, we performed a systematic literature search on PubMed, Google Scholar, and Web of Science for literature updated from 2010 to 1 March 2021. Inclusion criteria for studies were observational design and Randomized Controlled Trials (RCTs); written in English; primary research only; based on adult patients, and human research only. RESULTS: We identified nine studies on the link between NAFLD and IBD. Among these, two described the genetic predisposition to NAFLD of patients with IBD. Four reported an association between MetS and NAFLD in IBD patients. Regarding medications, none of four studies included. detected a relationship between NAFLD onset and IBD treatment (corticosteroids, immunomodulators, methotrexate, or biologics). However, a retrospective study showed a protective effect of anti-TNF alpha therapies against altered liver enzymes. CONCLUSIONS: In this interplay between genetic, metabolic, drug, and inflammatory factors, the underlying pathogenic mechanisms behind NAFLD in IBD are still far from clear. Further studies are needed to better clarify the role of individual components influencing the development of NAFLD in IBD.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Farmakologi och toxikologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Pharmacology and Toxicology (hsv//eng)

Keyword

Inflammatory bowel disease
Non-alcoholic fatty liver disease
Metabolic
syndrome
Transient elastography
Controlled attenuation parameter
Liver stiffness
Anti-tumor necrosis factor alpha
Gut microbiota
sinusoidal endothelial-cells
metabolic syndrome
confers
susceptibility
risk-factor
pnpla3
epidemiology
association
infliximab
microbiota
variant
Pharmacology & Pharmacy

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view